74. 下垂体性PRL分泌亢進症 Prolactin secreting pituitary adenoma Clinical trials / Disease details


臨床試験数 : 18 薬物数 : 33 - (DrugBank : 10) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 65

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01620138
(ClinicalTrials.gov)
March 201018/9/2011Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant ProlactinomasSomatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine AgonistNon-functioning Pituitary Adenomas;ProlactinomasDrug: Pasireotide;Drug: cabergolineUniversidade Federal do Rio de JaneiroNULLCompleted18 YearsN/AAll21Phase 2/Phase 3Brazil
2EUCTR2008-007348-32-IT
(EUCTR)
07/09/200907/08/2009An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NDAn open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - ND 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelsons syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10051747
Product Name: PASIREOTIDE
Product Code: SOM230
INN or Proposed INN: PASIREOTIDE
Product Name: PASIREOTIDE
Product Code: SOM230
INN or Proposed INN: PASIREOTIDE
Product Name: PASIREOTIDE
Product Code: SOM230
INN or Proposed INN: PASIREOTIDE
NOVARTIS FARMANULLNot RecruitingFemale: yes
Male: yes
70France;Spain;Germany;Italy
3EUCTR2008-007348-32-DE
(EUCTR)
12/08/200930/06/2009An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NAAn open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA The following tumors are included:1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelson's syndrome
MedDRA version: 14.1;Level: LLT;Classification code 10062476;Term: Neuroendocrine tumor;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
120Phase 2United States;Spain;Russian Federation;Colombia;Italy;France;Mexico;Canada;Argentina;Brazil;Australia;South Africa;Germany
4EUCTR2008-007348-32-FR
(EUCTR)
06/05/200905/06/2009An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NAAn open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NA The following tumors are included:1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma,2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA)3. Ectopic ACTH-secreting (EAS) tumors4. Nelson’s syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10062476;Term: Neuroendocrine tumor
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Product Name: pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
100Phase 2France;Spain;Germany;Italy
5EUCTR2006-007036-95-DE
(EUCTR)
02/07/200823/01/2009Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept studyMonocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study Prolactinoma
MedDRA version: 9.1;Level: LLT;Classification code 10036832;Term: Prolactinoma
Product Code: SOM230
INN or Proposed INN: Pasireotide
Product Code: SOM230
INN or Proposed INN: Pasireotide
Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für EndokrinologieNULLNot RecruitingFemale: yes
Male: yes
Germany